11:55 AM EDT, 06/12/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) on Thursday reported "encouraging" phase 1b results for bleximenib, an investigational oral menin inhibitor, when used in combination with venetoclax and azacitidine to treat acute myeloid leukemia.

The study focused on acute myeloid leukemia cases with KMT2A gene rearrangements or NPM1 mutations, including both newly diagnosed patients ineligible for intensive chemotherapy and those with relapsed or refractory disease.

At the recommended phase 2 dose, patients with relapsed or refractory AML achieved an overall response rate of 82% and a composite complete response rate of 59%. For newly diagnosed, intensive chemo-ineligible patients, the ORR was 90% and the cCR rate was 75%, the company said.

Safety data showed the combination was generally well tolerated, with no dose-limiting QTc prolongation signals and low rates of differentiation syndrome.

Price: 155.67, Change: +0.41, Percent Change: +0.26